Articles

Autoimmune diseases (ADs) are a series of multifaceted conditions associated with loss of immune homeostasis, leading to self-inflicted destruction of self-tissues. The conditions arise from self-antigens mistakenly identified as foreign by the immune system, leading to chronic inflammatory responses, progressive tissue damage, and organ dysfunction. ADs like systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), multiple sclerosis (MS), and type 1 diabetes mellitus (T1DM) impact millions of people globally, and this is a developing issue in population health. These disorders have a multifactorial pathogenesis, involving a combination of genetically predisposed factors, environmental factors, hormonal factors, and immune regulatory deficiencies. Immune homeostasis is maintained by central and peripheral tolerance mechanisms, which eliminate or suppress autoreactive T and B cells; when these mechanisms fail, autoimmune responses are driven by the survival of autoreactive T and B cells. Such immune abnormalities are linked to dysregulation of cytokine production, immune complex generation, complement activation (CA), and activation of chronic inflammatory signaling pathways. Recent developments in immunology and molecular medicine have enhanced understanding of the pathogenesis of ADs and led to improved diagnostic and treatment approaches. Serological biomarkers, especially antinuclear antibodies (ANA), anti-double-stranded DNA antibodies (anti-dsDNA), rheumatoid factor (RF), and anti-cyclic citrullinated peptide antibodies (anti-CCP), will continue to play an important role in the diagnosis and monitoring of disease. Moreover, recent diagnostic methods, such as flow cytometry, molecular tests, and sophisticated imaging tools, have improved the ability to monitor immune deregulation and disease progression. The new strategies, such as multi-omics technologies, microRNA profiling, and genetic risk assessment, are offering new possibilities for early detection and personalized medicine. The review summarizes the immunopathogenesis of major ADs and outlines existing diagnostic perspectives and new strategies to improve disease management and therapeutic outcomes.